Dr. Eng on the Potential of Trastuzumab Deruxtecan in HER2+ mCRC

Video

In Partnership With:

Cathy Eng, MD, FACP, FASCO, discusses the potential of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic colorectal cancer.

Cathy Eng, MD, FACP, FASCO, David H. Johnson Chair in Surgical and Medical Oncology; co-leader of the Gastrointestinal (GI) Cancer Research Program; professor of medicine in hematology and oncology; co-director of GI Oncology; vice chair of the SWOG GI Committee; and director of the VICC Young Adult Cancers Initiative at Vanderbilt-Ingram Cancer Center, discusses the potential of fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with HER2-positive metastatic colorectal cancer (mCRC).

Trastuzumab deruxtecan is one particular agent of interest in mCRC, having been evaluated in patients who had previously received a HER2-targeted therapy, according to Eng. Although HER2 positivity is rare in CRC, occurring in only 5% of patients, trastuzumab (Herceptin) has previously demonstrated benefit in this population; however, these patients may experience disease progression on the agent, Eng notes. As such, trastuzumab deruxtecan is being evaluated in the phase 2 DESTINY-CRC01 trial (NCT03384940) in patients who had previously received trastuzumab, Eng explains.

In December 2019, trastuzumab deruxtecan received FDA approval for use in patients with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti–HER2-based regimens in the metastatic setting. More recently, in January 2021, the antibody-drug conjugate received regulatory approval for use in patients with locally advanced or metastatic HER2-positive gastric gastroesophageal junction adenocarcinoma who have previously received a trastuzumab-based regimen.

Related Videos
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Brian I. Rini, MD, FASCO
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center